{"classes":[{"categories":[{"measurements":[{"comment":"Not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"12.6","upperLimit":"NA","value":"31.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"PD-L1 < 1%"},{"categories":[{"measurements":[{"comment":"Not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"PD-L1 >= 1%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"DOR was measured from the time measurement criteria are first met for CR/PR, as defined in Outcome Measure 13, whichever was recorded first, until the first date of recurrent or PD or death due to any cause in participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by IHC. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG000","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"MEDIAN","populationDescription":"The biomarker analysis set (BAS) included all participants in the FAS who had samples evaluable for PD-L1 assay. Here, 'Overall number of participants analyzed' signifies participants with confirmed CR or PR that are evaluable for this outcome measure and \"Number analyzed\" is the number of participants in each row category. Only Group 6 was planned for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 65 months (treatment period + follow-up including survival follow-up)","title":"DOR by Independent Central Review for Participants With Evaluable PD-L1 Assays","type":"SECONDARY","unitOfMeasure":"months"}